Prelude Capital Management, LLC Obs Eva Sa Transaction History

Prelude Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$2.48 - $8.1 $642 - $2,097	-259 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$8.22 - $11.2 $6,773 - $9,228	-824 Reduced 76.08%	259 $2,000
Q2 2019 Aug 14, 2019	BUY	$10.05 - $14.25 $7,969 - $11,300	793 Added 273.45%	1,083 $12,000
Q1 2019 May 15, 2019	SELL	$11.82 - $14.48 $200 - $246	-17 Reduced 5.54%	290 $4,000
Q4 2018 Feb 14, 2019	BUY	$10.8 - $17.94 $118 - $197	11 Added 3.72%	307 $4,000
Q3 2018 Nov 14, 2018	BUY	$10.92 - $18.18 $196 - $327	18 Added 6.47%	296 $5,000
Q2 2018 Aug 14, 2018	SELL	$10.0 - $17.87 $1,640 - $2,930	-164 Reduced 37.1%	278 $4,000
Q1 2018 May 15, 2018	BUY	$9.36 - $15.22 $4,137 - $6,727	442 New	442 $6,000

88K

Ticker OBSV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,499,200
Description
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometrio...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.